MCKESSON CORP reported fiscal 2026 fourth quarter and full year ended March 31, 2026 results: revenue Consolidated revenues of $96.3 billion, net income Net income attributable to McKesson Corporation 1,682, EPS Earnings per diluted share of $13.71.
“2026 - McKesson Corporation (NYSE:MCK) today announced results for the fourth quarter and fiscal year ended March 31, 2026. Fourth Quarter Highlights: • Consolidated revenues of $96.3 billion increased 6%. • Earnings per diluted share of $13.71 increased $3.70. • Adjusted Earnings per Diluted Share of $11.69 increased 16%. • McKesson entered into a $2.25 billion”
“The Existing 364-Day Credit Facility was scheduled to mature in May 2026 and provided a revolving line of credit of up to $1.0 billion.”
Material Agreements
MCKESSON CORP entered into Credit Agreement with Bank of America, N.A. valued at $5.0 billion (effective 2026-04-24).
“On April 24, 2026, McKesson Corporation ("McKesson" or the "Company") entered into a Credit Agreement (the "New Revolving Credit Facility") among the Company, as borrower, the lenders party thereto, Bank of America, N.A., as administrative agent, and the other parties thereto.”
Debt Financings
MCKESSON CORP incurred credit facility of $750.0 million senior secured term A loan facility due 2031, $250.0 million senior secured term A loan facility due 2028 with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent at Adjusted Term SOFR Rate plus applicable margin of 1.250% per annum or Base Rate maturing Term Loan A-1 Facility due 2031, Term Loan A-2 Facility due 2028, Revolving Credit Facility matures April 1, 2031.
“On April 1, 2026, certain of McKesson Corporation’s (the “Company”) subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent providing for (i) a $750.0 million senior secured term “A” loan facility due 2031 (the “Term Loan A-1 Facility”), (ii) a $250.0 million senior secured term “A” loan facility due 2028 (the “Term Loan A-2 Facility” and, together with the Term Loan A-1 Facility, the “Term Loan A Facilities”) and (iii) a $1,000.0 million senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan A Facilities, the “Senior Secured Credit Facilities”).”
Material Agreements
MCKESSON CORP entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent valued at $2,000.0 million (effective 2026-04-01).
“On April 1, 2026, certain of McKesson Corporation’s (the “Company”) subsidiaries, including McKesson Medical-Surgical Top Holdings, Inc. (the “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent providing for (i) a $750.0 million senior secured term “A” loan facility due 2031 (the “Term Loan A-1 Facility”), (ii) a $250.0 million senior secured term “A” loan facility due 2028 (the “Term Loan A-2 Facility” and, together with the Term Loan A-1 Facility, the “Term Loan A Facilities”) and (iii) a $1,000.0 million senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan A Facilities, the “Senior Secured Credit Facilities”).”
Susan R. Salka departed as Director at MCKESSON CORP.
“Linda Mantia and Susan R. Salka will not be standing for re-election at the Corporation’s 2024 annual meeting of shareholders (“Annual Meeting”), and their terms will expire effective at the Annual Meeting.”
Linda Mantia departed as Director at MCKESSON CORP.
“Linda Mantia and Susan R. Salka will not be standing for re-election at the Corporation’s 2024 annual meeting of shareholders (“Annual Meeting”), and their terms will expire effective at the Annual Meeting.”
Deborah Dunsire was elected as Director at MCKESSON CORP.
“On May 31, 2024, the Board of Directors (“Board”) of McKesson Corporation (“Corporation”) elected Deborah Dunsire, M.D. as a director of the Corporation and appointed her to the Board’s Compensation and Talent Committee and Finance Committee, effective June 3, 2024.”
Earnings Releases
MCKESSON CORP reported preliminary financial results for the quarter and fiscal year ended on March 31, 2024.
“On May 7, 2024, McKesson Corporation (“Company”) reported the Company’s preliminary results for the quarter and fiscal year ended on March 31, 2024”
Earnings Releases
MCKESSON CORP reported the third quarter ended December 31, 2023 results: revenue $80,898, net income $589, EPS $4.42. Guidance raised.
“December 31, 2023. Fiscal 2024 Third Quarter Result Summary Third Quarter Year-to-Date ($ in millions, except per share amounts) FY24 FY23 Change FY24 FY23 Change Revenues $ 80,898 $ 70,490 15 % $ 232,596 $ 207,801 12 % Income from Continuing Operations 2 589 1,078 (45) 2,211 2,776 (20) Adjusted Earnings 2,3 1,032 972 6 2,866 2,697 6 Earnings per Diluted”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.